Potential Therapeutic Targets for the Primary Gallbladder Carcinoma: Estrogen Receptors

  • Zhang, Ling-Qiang (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhang, Xiu-De (Department of Endocrinology, the Second Lanzhou University Hospital) ;
  • Xu, Jia (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wan, Yong (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Qu, Kai (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhang, Jing-Yao (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wang, Zhi-Xin (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wei, Ji-Chao (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Meng, Fan-Di (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Tai, Ming-Hui (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhou, Lei (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Chang (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University)
  • Published : 2013.04.30


Gallbladder carcinoma, the most frequent malignant neoplasm of the biliary tract system, has always been considered to feature late clinical presentation and diagnosis, limited treatment options and an extremely poor prognosis. In recent years, while the incidence of gallbladder cancer has appeared to be on the increase, the available treatment methods have not greatly improved survival of the affected patients. Thus, exploring new therapeutic targets for this devastating disease is an urgent matter at present. Epidemical studies have demonstrated that the incidence of gallbladder carcinoma exhibits a distinct gender bias, affecting females two to three times more than males, pointing to crucial roles of estrogen. It is well known that estrogen acts on target tissues by binding to estrogen receptors (ERs), which are mainly divided into three subtypes, $ER{\alpha}$, $ER{\beta}$ and $ER{\gamma}$. $ER{\alpha}$ and $ER{\beta}$ appear to have overlapping but also unique even opposite biological effects. As important pathogenic mediators, ERs have been considered to relate to several kinds of tumors. In gallbladder carcinoma tissue, ERs have been shown to be positively expressed, and ERs expression levels are associated with differentiation and prognosis of this cancer. Nevertheless, the exact mechanisms of estrogen inducing growth of gallbladder carcinoma remain poorly understood. On the base of the current investigations, we deduce that estrogen participates in promotion of gallbladder carcinoma by influencing the formation of gallstones, stimulating angiogenesis, and promoting abnormal proliferation. Since ERs mediate the carcinogenic actions of estrogen in gallbladder, and therapy targeting ERs may provide new directions for gallbladder carcinoma. Therefore, it should be stressed that ERs are potential therapeutic targets for gallbladder carcinoma.


  1. Ahrens W, Timmer A, Vyberg M, et al (2007). Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroen Hepat, 19, 623-30.
  2. Albores-Saavedra J, Henson DE, Moran-Portela D,Lino-Silva S (2008). Cribriform carcinoma of the gallbladder: a clinicopathologic study of 7 cases. Am J Surg Pathol, 32, 1694-8.
  3. Alvaro D, Alpini G, Onori P, et al (2000). Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology, 119, 1681-91.
  4. Alvaro D, Mancino MG, Onori P, et al (2006). Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol, 12, 3537-45.
  5. Alvaro D, Onori P, Metalli VD, et al (2003). Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology, 36, 297-304.
  6. Boutros C, Gary M, Baldwin K,Somasundar P (2012). Gallbladder cancer: Past, present and an uncertain future. Surg Oncol, 21, e183-91.
  7. Chen A,Huminer D (1991). The role of estrogen receptors in the development of gallstones and gallbladder cancer. Med Hypotheses, 36, 259-60.
  8. Chia S, Bryce C,Gelmon K (2005). The 2000 EBCTCG overview: a widening gap. Lancet, 365, 1665-6.
  9. Cho SY, Kim SH, Park SJ, et al (2010). Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol, 102, 87-93.
  10. Cirillo D J, Wallace RB, Rodabough RJ, et al (2005). Effect of estrogen therapy on gallbladder disease. JAMA, 293, 330-9.
  11. de Aretxabala X, Roa I, Berrios M, et al (2006). Chemoradiotherapy in gallbladder cancer. J Surg Oncol, 93, 699-704.
  12. DeMorrow S (2009). Cholangiocarcinoma: Estrogen-induced autocrine effects of VEGF on cell proliferation. Digest Liver Dis, 41, 164-5.
  13. Duan LP, Wang HH, Ohashi A,Wang DQH (2006). Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol-Gastr L, 290, G269-76.
  14. Dunnwald LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, R6.
  15. Evans RM (1988). The steroid and thyroid hormone receptor superfamily. Science, 240, 889-95.
  16. Everson GT, McKinley C,Kern F, Jr. (1991). Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest, 87, 237-46.
  17. Fernandez E, Gallus S, Bosetti C, et al (2003). Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer, 105, 408-12.
  18. Fisher RI, Neifeld JP,Lippman ME (1976). Oestrogen receptors in human malignant melanoma. Lancet, 308, 337-9.
  19. Fouassier L, Rosenberg P, Mergey M, et al (2009). Ezrin-radixinmoesin-binding phosphoprotein (EBP50), an estrogeninducible scaffold protein, contributes to biliary epithelial cell proliferation. Am J Pathol, 174, 869-80.
  20. Furuse J (2008). Postoperative adjuvant treatments for biliary tract cancer. J Hepato-Biliary-Pan, 15, 463-7.
  21. Gabbi C, Kim HJ, Barros R, et al (2010). Estrogen-dependent gallbladder carcinogenesis in LXR${\beta}$-/-female mice. Proc Natl Acad Sci USA, 107, 14763-8.
  22. Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A,Sivridis E (2003). Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol, 29, 879-83.
  23. Greenway B, Iqbal M, Johnson P,Williams R (1981). Oestrogen receptor proteins in malignant and fetal pancreas. BMJ, 283, 751-3.
  24. Gupta P, Agarwal A, Gupta V, et al (2012). Expression and clinicopathological significance of estrogen and progesterone receptors in gallbladder cancer. Gastrointest Cancer Res, 5, 41-7.
  25. Hanahan D,Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
  26. Hawkins MB, Thornton JW, Crews D, et al (2000). Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. P Natl Acad Sci USA, 97, 10751-6.
  27. Honma N, Horii R, Iwase T, et al (2008). Clinical importance of estrogen receptor-${\beta}$ evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol, 26, 3727-34.
  28. Hsing A, Gao Y, Han T, et al (2007). Gallstones and the risk of biliary tract cancer: a population-based study in China. Brit J Cancer, 97, 1577-82.
  29. Hunsawong T, Singsuksawat E, In-chon N, et al (2012). Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. J Cancer Res Clin, 138, 1311-20.
  30. Isse K, Specht SM, Lunz III JG, et al (2010). Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology, 51, 869-80.
  31. Ito H, Matros E, Brooks DC, et al (2004). Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg, 8, 183-90.
  32. Iyer V, Klebba I, McCready J, et al (2012). Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Res, 72, 2705-13.
  33. Kamat A, Rajoria S, George A, et al (2011). Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg, 137, 1146-53.
  34. Ko CY, Schmit P, Cheng L,Thompson JE (1995). Estrogen receptors in gallbladder cancer: detection by an improved immunohistochemical assay. Am Surg, 61, 930-3.
  35. Lazcano-Ponce EC, Miquel JF, Munoz N, et al (2001). Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin, 51, 349-64.
  36. Lindberg MK, Moverare S, Skrtic S, et al (2003). Estrogen receptor (ER)-${\beta}$ reduces ER${\alpha}$-regulated gene transcription, supporting a "Ying Yang" relationship between ER${\alpha}$ and ER${\beta}$ in mice. Mol Endocrinol, 17, 203-8.
  37. Liu MM, Albanese C, Anderson CM, et al (2002). Opposing action of estrogen receptors ${\alpha}$ and ${\beta}$ on cyclin D1 gene expression. J Biol Chem, 277, 24353-60.
  38. Lydon JP (2010). Stem cells: Cues from steroid hormones. Nature, 465, 695-6.
  39. Mancino A, Mancino M, Glaser S, et al (2009). Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Digest Liver Dis, 41, 156-63.
  40. Mann S, Laucirica R, Carlson N, et al (2001). Estrogen receptor beta expression in invasive breast cancer. Hum Pathol, 32, 113-8.
  41. Mueller MD, Vigne JL, Minchenko A, et al (2000). Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors ${\alpha}$ and ${\beta}$. P Natl Acad Sci USA, 97, 10972-7.
  42. Nakamura S, Muro H,Suzuki S (1989). Estrogen and progesterone receptors in gallbladder cancer. Surg Today, 19, 189-94.
  43. Nevin JE, Moran TJ, Kay S, King R (1976). Carcinoma of the gallbladder. Staging, treatment, and prognosis. Cancer, 37, 141-8.<141::AID-CNCR2820370121>3.0.CO;2-Y
  44. Ohnami S, Nakata H, Nagafuchi Y, Zeze F,Eto S (1988). Estrogen receptors in human gastric, hepatocellular, and gallbladder carcinomas and normal liver tissues. Gan To Kagaku Ryoho, 15, 2923-8.
  45. Park JS, Jung WH, Kim JK, et al (2009). Estrogen receptor alpha, estrogen receptor beta, and progesterone receptor as possible prognostic factor in radically resected gallbladder carcinoma. J Surg Res, 152, 104-10.
  46. Park SK, Andreotti G, Rashid A, et al (2010). Polymorphisms of estrogen receptors and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Carcinogenesis, 31, 842-6.
  47. Pequeux C, Raymond-Letron I, Blacher S, et al (2012). Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res, 72, 3010-9.
  48. Petitti DB (1988). Estrogen use and gallstone disease. Am J Public Health, 78, 1365.
  49. Quan ZW, Wu K, Wang J, et al (2001). Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg, 193, 380-3.
  50. Reichen J, Karlaganis G,Kern F, Jr. (1987). Cholesterol synthesis in the perfused liver of pregnant hamsters. J Lipid Res, 28, 1046-52.
  51. Roa I, Araya J, Villaseca M, et al (1995). Gallbladder cancer: immunohistochemical expression of the protein related to estrogen receptor (p29) and of the protein induced by estrogen (pS2)]. Revista medica de Chile, 123, 1333.
  52. Shaffer EA (2008). Gallbladder cancer: the basics. Gastroenterol Hepatol (NY), 4, 737-41.
  53. ShuklA PJ, Barreto SG, Gupta P, et al (2007). Is there a role for estrogen and progesterone receptors in gall bladder cancer?. HPB, 44, 285-8.
  54. Sica V, Nola E, Contieri E, et al (1984). Estradiol and progesterone receptors in malignant gastrointestinal tumors. Cancer Res, 44, 4670-4.
  55. Spillman MA, Manning NG, Dye WW, et al (2010). Tissuespecific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res, 70, 8927-36.
  56. Srivastava A, Sharma KL, Srivastava N, Misra S, Mittal B (2012). Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy. PloS One, 7, e40162.
  57. Stedman KE, Moore GE, Morgan RT (1980). Estrogen receptor proteins in diverse human tumors. Arch Surg, 115, 244-8.
  58. Stinton LM, Shaffer EA (2012). Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver, 6, 172-87.
  59. Stossi F, Barnett DH, Frasor J, et al (2004). Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) ${\alpha}$ or ER${\beta}$ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology, 145, 3473-86.
  60. Sumi K, Matsuyama S, Kitajima Y, Miyazaki K (2004). Loss of estrogen receptor${\beta}$ expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. Oncol Rep, 12, 979-84.
  61. Sun XN, Cao WG, Wang X, et al (2011). Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol, 32, 1183-90.
  62. Venniyoor A (2008). Cholesterol gallstones and cancer of gallbladder (CAGB): molecular links. Med Hypotheses, 70, 646-53.
  63. Wallace AE, Gibson DA, Saunders PTK,Jabbour HN (2010). Inflammatory events in endometrial adenocarcinoma. J Endocrinol, 206, 141-57.
  64. Wang HH, Afdhal NH, Wang DQ (2004). Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiolinduced murine cholesterol gallstones. Gastroenterology 127, 239-49.
  65. Wang HH, Afdhal NH, Wang DQH (2006). Overexpression of estrogen receptor ${\alpha}$ increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. J Lipid Res, 47, 778-86.
  66. Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQH (2009). New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. BBAMol Cell Res, 1791, 1037-47.
  67. Welsh AW, Lannin DR, Young GS, et al (2012). Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res, 18, 118-26.
  68. Wistuba II,Gazdar AF (2004). Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer, 4, 695-706.
  69. Yamaguchi Y, Hayashi S (2009). Estrogen-related cancer microenvironment of breast carcinoma. Endocr J, 56, 1-7.
  70. Yamamoto M, Nakajo S, Tahara E (1990). Immunohistochemical analysis of estrogen receptors in human gallbladder cancer. Pathol Int, 40, 14-21.

Cited by

  1. MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor vol.12, pp.1, 2012,
  2. Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway vol.106, pp.7, 2015,
  3. Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer vol.15, pp.1, 2015,
  4. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India vol.16, pp.13, 2015,
  5. Surgical treatment of gallbladder carcinoma: a critical review vol.67, pp.4, 2015,
  6. Targeted Therapy in Biliary Tract Cancers vol.16, pp.10, 2015,
  7. PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40) pp.1873-961X, 2019,